logo-loader

Faron Pharmaceuticals CEO details new global pneumonia trial for Traumakine

Published: 00:48 02 Apr 2020 AEDT

Faron Pharmaceuticals Oy's (LON:FARN) chief executive Dr Markku Jalkanen tells Proactive London's Andrew Scott its drug Traumakine has been admitted to a large-scale global programme that will assess its potential in treating severe pneumonia.

The study also includes patients suffering from the latest virus outbreak.

The interferon beta-1 formulation will be delivered intravenously, which he says offers the best “delivery route” for critically ill patients.

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18